<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03106831</url>
  </required_header>
  <id_info>
    <org_study_id>PX2016007</org_study_id>
    <nct_id>NCT03106831</nct_id>
  </id_info>
  <brief_title>Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery</brief_title>
  <official_title>Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vasoplegic syndrome is a common complication after cardiac surgery. Low dose vasopressin can
      up-regulate blood pressure and improve clinical outcomes compared with norepinephrine (mainly
      acute kidney injury Anesthesiology 2017; 126:85-93). Pituitrin is used as a substitute for
      vasopressin in our center, which contains both vasopressin and oxytocin. Oxytocin may
      alleviate inflammatory process-associated kidney injury (Peptides 2006;27:2249-57).
      Therefore, the investigators hypothesize Pituitrin may be preferable to norepinephrine in the
      renal protection of patients with vasoplegic syndrome after cardiac surgery. Moreover, the
      serum levels of vasopressin, catecholamine, corticosteroid and corticotropin-releasing
      hormone will be measured.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 10, 2017</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of in-hospital acute renal injury</measure>
    <time_frame>30 days</time_frame>
    <description>Acute renal injury (AKI) is defined as any of the following: (1) increase in serum creatinine (SCr) by ≥ 26.5lmol/l in 48 hours; (2) increase in SCr to ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or (3) urine output &lt; 0.5 ml/kg/h for 6 hours (urine output is only assessed when the CRRT machine is absent or with a fluid removal rate of 0 ml/h).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of new arrhythmias</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of new arrhythmias after cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormone levels</measure>
    <time_frame>30 days</time_frame>
    <description>Serum hormone levels after cardiac surgery, including vasopressin, catecholamine, corticosteroid and corticotropin-releasing hormone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ECMO or LVAD support</measure>
    <time_frame>30 days</time_frame>
    <description>Receiving extracorporeal membrane oxygenation (ECMO) or left ventricle assist device (LVAD) support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration on ventilator support</measure>
    <time_frame>30 days</time_frame>
    <description>Duration on ventilator support after cardiac surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>30 days</time_frame>
    <description>ICU length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay after cardiac surgery</measure>
    <time_frame>30 days</time_frame>
    <description>Hospital length of stay after cardiac surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Postoperative Vasoplegic Syndrome</condition>
  <arm_group>
    <arm_group_label>Pituitrin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norepinephrine arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pituitrin infusion</intervention_name>
    <description>To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.</description>
    <arm_group_label>Pituitrin arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine infusion</intervention_name>
    <description>To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.</description>
    <arm_group_label>Norepinephrine arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients diagnosed as vasoplegic syndrome(defined as mean arterial pressure less than 65
        mmHg resistant to fluid challenge and cardiac index greater than 2.2 L/min · m2) within 24
        hours after cardiac surgery.

        Exclusion Criteria:

          1. Age &lt; 18 and &gt; 75 years.

          2. Received renal replacement therapy before cardiac surgery.

          3. Diagnosed as endocrine disease before cardiac surgery.

          4. Diagnosed as sever peripheral vascular disease before cardiac surgery.

          5. Extracorporeal membrane oxygenation support before admission.

          6. To receive heart transplantation.

          7. Infection on admission.

          8. Pregnant or maternal patients.

          9. Refusal of consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Wang, PhD., MD.</last_name>
    <phone>86 15010516438</phone>
    <email>914286855@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hong Wang, PhD., MD.</last_name>
      <phone>86 15010516438</phone>
      <email>914286855@qq.com</email>
    </contact>
    <investigator>
      <last_name>Hong Wang, PhD., MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2017</study_first_posted>
  <last_update_submitted>October 10, 2017</last_update_submitted>
  <last_update_submitted_qc>October 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Xiaotong Hou</investigator_full_name>
    <investigator_title>Director of Center for Cardiac Intensive Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Vasoplegia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

